HighGravityDataCurrent guidance
34 items
Elevance Health
Guidance from Elevance Health’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Jul 15, 2026
Data checked
Jul 15, 2026
What changed in the Jul 15, 2026 release
Each item compared with the same item in the previous release (Apr 22, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Raised | Adjusted diluted EPS | for FY2026 | “at least $26.75” | “at least $27.00” | Filing ↗ |
| Raised | Adjusted shareholders' earnings per diluted share | for FY2026 | “At least $26.75” | “At least $27.00” | Filing ↗ |
| Raised | Diluted EPS | for FY2026 | “at least $19.85” | “at least $20.10” | Filing ↗ |
| Raised | Shareholders' earnings per diluted share | for FY2026 | “At least $19.85” | “At least $20.10” | Filing ↗ |
| Raised | Operating cash flow | for FY2026 | “at least $5.5 billion” | “at least $6.0 billion” | Filing ↗ |
| Reiterated | Adjusted EPS growth | for FY2027 | “at least 12%” | “at least 12%” | Filing ↗ |
Show 21 items not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Operating Revenue Growth Rate: Carelon Services | for FY2026 | “Low single digit growth” | — | Filing ↗ |
| Not restated | Premium Revenue | for FY2026 | “Mid single digit decline” | — | Filing ↗ |
| Not restated | Product Revenue | for FY2026 | “Mid single digit growth” | — | Filing ↗ |
| Not restated | Total Operating Revenue | for FY2026 | “Low single digit decline” | — | Filing ↗ |
| Not restated | Projected FY 2026 adjusted diluted EPS | for FY2026 | “at least $25.50” | — | Filing ↗ |
| Not restated | Projected FY 2026 GAAP diluted EPS | for FY2026 | “at least $22.30” | — | Filing ↗ |
| Not restated | Long-term earnings algorithm and segment margin targets | for the long term | “Reaffirming long-term earnings algorithm; recalibrating segment margin targets” | — | Filing ↗ |
| Not restated | Adjusted Effective Tax Rate | for FY2026 | “22.0% - 24.0%” | — | Filing ↗ |
| Not restated | Amortization of Intangible Assets | for FY2026 | “($440) million” | — | Filing ↗ |
| Not restated | Diluted Shares | for FY2026 | “219-220 million” | — | Filing ↗ |
| Not restated | Interest Expense | for FY2026 | “($1,530) million” | — | Filing ↗ |
| Not restated | Net Investment income | for FY2026 | “$1,875 million” | — | Filing ↗ |
| Not restated | Service Fees | for FY2026 | “Mid single digit growth” | — | Filing ↗ |
| Not restated | Year-End Medical Enrollment: Commercial Fee-Based | for FY2026 | “27,200 - 27,500” | — | Filing ↗ |
| Not restated | Year-End Medical Enrollment: Commercial Risk-Based | for FY2026 | “4,150 - 4,250” | — | Filing ↗ |
| Not restated | Year-End Medical Enrollment: Federal Employee Program | for FY2026 | “Approximately 1,550” | — | Filing ↗ |
| Not restated | Year-End Medical Enrollment: Medicaid | for FY2026 | “7,650 - 7,850” | — | Filing ↗ |
| Not restated | Year-End Medical Enrollment: Medicare Advantage | for FY2026 | “1,775 - 1,875” | — | Filing ↗ |
| Not restated | Year-End Medical Enrollment: Medicare Supplement | for FY2026 | “Approximately 850” | — | Filing ↗ |
| Not restated | Year-End Medical Enrollment: Risk-Based | for FY2026 | “15,975 - 16,375” | — | Filing ↗ |
| Not restated | Year-End Medical Enrollment: Total | for FY2026 | “43,175 - 43,875” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Operating Revenue Growth Rate: Carelon Services | “Low single digit growth” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Premium Revenue | “Mid single digit decline” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Product Revenue | “Mid single digit growth” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Total Operating Revenue | “Low single digit decline” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Adjusted diluted EPS | “at least $27.00” | for FY2026 | Company-defined | Apr 22, 2026 | 2 | Filing ↗ |
| Adjusted shareholders' earnings per diluted share | “At least $27.00” | for FY2026 | Company-defined | Jan 28, 2026 | 3 | Filing ↗ |
| Diluted EPS | “at least $20.10” | for FY2026 | GAAP-tied | Apr 22, 2026 | 2 | Filing ↗ |
| GAAP Operating Margin vs. 2025: Carelon Services | “0 - 25 bps” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| GAAP Operating Margin vs. 2025: Health Benefits | “(50) - (25) bps” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Projected FY 2026 adjusted diluted EPS | “at least $25.50” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Projected FY 2026 GAAP diluted EPS | “at least $22.30” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Shareholders' earnings per diluted share | “At least $20.10” | for FY2026 | GAAP-tied | Jan 28, 2026 | 3 | Filing ↗ |
| Adjusted Effective Tax Rate | “22.0% - 24.0%” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Adjusted Operating Expense Ratio | “10.6% +/- 50 bps” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Adjusted Operating Gain | “At least $6.8 billion” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Amortization of Intangible Assets | “($440) million” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Benefit Expense Ratio | “90.2% +/- 50 bps” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Diluted Shares | “219-220 million” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Dividend | “$1.72 per share” | for Q3 FY2026 | Declared action | Jul 15, 2026 | 1 | Filing ↗ |
| Interest Expense | “($1,530) million” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Net Investment income | “$1,875 million” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Operating cash flow | “at least $6.0 billion” | for FY2026 | GAAP-tied | Apr 22, 2026 | 2 | Filing ↗ |
| Operating Cash Flow | “At least $5.5 billion” | for FY2026 | GAAP-tied | Jan 28, 2026 | 1 | Filing ↗ |
| Quarterly dividend declared | “$1.72 per share” | for Q3 FY2026 | Declared action | Jul 15, 2026 | 1 | Filing ↗ |
| Service Fees | “Mid single digit growth” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Year-End Medical Enrollment: Commercial Fee-Based | “27,200 - 27,500” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Year-End Medical Enrollment: Commercial Risk-Based | “4,150 - 4,250” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Year-End Medical Enrollment: Federal Employee Program | “Approximately 1,550” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Year-End Medical Enrollment: Medicaid | “7,650 - 7,850” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Year-End Medical Enrollment: Medicare Advantage | “1,775 - 1,875” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Year-End Medical Enrollment: Medicare Supplement | “Approximately 850” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Year-End Medical Enrollment: Risk-Based | “15,975 - 16,375” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Year-End Medical Enrollment: Total | “43,175 - 43,875” | for FY2026 | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
Next year and medium term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Adjusted EPS growth | “at least 12%” | for FY2027 | Company-defined | Jan 28, 2026 | 2 | Filing ↗ |
Long term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Average annual growth in adjusted diluted EPS | “at least 12%” | for the long term | Company-defined | Jul 17, 2025 | 1 | Filing ↗ |
| Long-term earnings algorithm and segment margin targets | “Reaffirming long-term earnings algorithm; recalibrating segment margin targets” | for the long term | Company-defined | Jan 28, 2026 | 1 | Filing ↗ |
| Share repurchase program authorization increase | “$8.0 billion increase” | for the long term | Declared action | Oct 17, 2024 | 1 | Filing ↗ |
No period stated
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Common stock repurchase program increase | “$8.0 billion” | — | Declared action | Oct 17, 2024 | 1 | Filing ↗ |
How one item moved
Adjusted shareholders' earnings per diluted share, for FY2026 — every statement across the year, each linked to its filing.
How your Healthcare payers & distributors sector group guides
12 companies in Healthcare payers & distributors. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| UnitedHealth Group | Oct 13, 2026 | 5 changes |
| Cardinal Health | Aug 11, 2026 | 13 changes |
| Cencora | Aug 5, 2026 | 11 changes |
| CVS Health | Aug 5, 2026 | 5 changes |
| McKesson | Aug 5, 2026 | 1 change |
| Labcorp | Jul 30, 2026 | 2 changes |
| The Cigna Group | Jul 30, 2026 | 3 changes |
| Humana | Jul 29, 2026 | 4 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2027 | FY2026 | FY2025 | FY2024 | Long-term | No period |
|---|---|---|---|---|---|---|
| Operating Revenue Growth Rate: Carelon Services | — | 1 statement | 1 statement | — | — | — |
| Operating Revenue Growth Rate: Health Benefits | — | — | 1 statement | — | — | — |
| Premium Revenue | — | 1 statement | 1 statement | — | — | — |
| Product Revenue | — | 1 statement | 1 statement | — | — | — |
| Total Operating Revenue | — | 1 statement | 1 statement | — | — | — |
The full record for Elevance Health and its Healthcare payers & distributors peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Jul 15, 2026 | FY2026 Q2 | 0001156039-26-000058 | 8 | Open filing ↗ |
| Apr 22, 2026 | FY2026 Q1 | 0001156039-26-000039 | 6 | Open filing ↗ |
| Jan 28, 2026 | FY2025 Q4 | 0001156039-26-000006 | 31 | Open filing ↗ |
| Oct 21, 2025 | FY2025 Q3 | 0001193125-25-244191 | 5 | Open filing ↗ |
| Jul 17, 2025 | FY2025 Q2 | 0001156039-25-000111 | 7 | Open filing ↗ |
| Apr 17, 2025 | FY2025 Q1 | 0001156039-25-000051 | 4 | Open filing ↗ |
| Jan 23, 2025 | FY2024 Q4 | 0001156039-25-000007 | 31 | Open filing ↗ |
| Oct 17, 2024 | FY2024 Q3 | 0001156039-24-000119 | 7 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error